share_log

F-3: Registration statement for specified transactions by certain foreign private issuers

F-3: Registration statement for specified transactions by certain foreign private issuers

F-3:交易註冊聲明
美股sec公告 ·  05/21 04:37
牛牛AI助理已提取核心訊息
Apollomics Inc., a biopharmaceutical company incorporated in the Cayman Islands and headquartered in the United States, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A ordinary shares for resale, which may be offered by certain selling securityholders from time to time. The registration statement includes a prospectus that provides detailed information about the company, its operations, and the offered securities. Apollomics Inc. will not receive any proceeds from the sale of shares by the selling securityholders. The company has obtained an undertaking from the Financial Secretary of the Cayman Islands, guaranteeing that no tax on profits, income...Show More
Apollomics Inc., a biopharmaceutical company incorporated in the Cayman Islands and headquartered in the United States, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The company, which focuses on the discovery and development of oncology therapies, has registered Class A ordinary shares for resale, which may be offered by certain selling securityholders from time to time. The registration statement includes a prospectus that provides detailed information about the company, its operations, and the offered securities. Apollomics Inc. will not receive any proceeds from the sale of shares by the selling securityholders. The company has obtained an undertaking from the Financial Secretary of the Cayman Islands, guaranteeing that no tax on profits, income, gains, or appreciations will be imposed on the company for a period of twenty years from the date of the undertaking. The registration statement also outlines the indemnification provisions for directors and officers, and the company's intention to maintain insurance coverage for them against certain claims. The company's Class A ordinary shares and warrants are listed on the Nasdaq Capital Market under the symbols 'APLM' and 'APLMW,' respectively.
Apollomics Inc. 是一家在開曼群島註冊成立、總部位於美國的生物製藥公司,已於2024年5月20日向美國證券交易委員會(SEC)提交了註冊聲明。該公司專注於腫瘤療法的發現和開發,已註冊A類普通股進行轉售,某些出售證券持有人可能會不時出售。註冊聲明包括一份招股說明書,其中提供了有關公司、其運營和所發行證券的詳細信息。Apollomics Inc. 不會從出售證券持有人出售股票中獲得任何收益。該公司已獲得開曼群島財政部長的承諾,保證自承諾之日起二十年內不對公司的利潤、收入、收益或增值徵稅。註冊聲明還概述了對董事和高級管理人員的賠償條款,以及公司爲他們維持某些索賠的保險的意圖。該公司的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克資本市場上市。
Apollomics Inc. 是一家在開曼群島註冊成立、總部位於美國的生物製藥公司,已於2024年5月20日向美國證券交易委員會(SEC)提交了註冊聲明。該公司專注於腫瘤療法的發現和開發,已註冊A類普通股進行轉售,某些出售證券持有人可能會不時出售。註冊聲明包括一份招股說明書,其中提供了有關公司、其運營和所發行證券的詳細信息。Apollomics Inc. 不會從出售證券持有人出售股票中獲得任何收益。該公司已獲得開曼群島財政部長的承諾,保證自承諾之日起二十年內不對公司的利潤、收入、收益或增值徵稅。註冊聲明還概述了對董事和高級管理人員的賠償條款,以及公司爲他們維持某些索賠的保險的意圖。該公司的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克資本市場上市。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。